amphetamine and Hepatitis C

amphetamine has been researched along with Hepatitis C in 5 studies

Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.

Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Research

Studies (5)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Effectiveness

The primary effectiveness outcome is defined as the rates of patient engagement in formal addiction treatment on the 30th day post enrollment. (NCT03023930)
Timeframe: 30 Days Post Enrollment

Implementation (Considered the Primary Outcome)

The primary implementation outcome will be evaluated assessing the rate of ED-initiated BUP therapy with referral for ongoing MAT (NCT03023930)
Timeframe: 12 months

Reviews

1 review available for amphetamine and Hepatitis C

Other Studies

4 other studies available for amphetamine and Hepatitis C